Unknown

Dataset Information

0

Impact of the Protein Data Bank on antineoplastic approvals.


ABSTRACT: Open access to 3D structure information from the Protein Data Bank (PDB) facilitated discovery and development of >90% of the 79 new antineoplastic agents (54 small molecules, 25 biologics) with known molecular targets approved by the FDA 2010-2018. Analyses of PDB holdings, the scientific literature and related documents for each drug-target combination revealed that the impact of public-domain 3D structure data was broad and substantial, ranging from understanding target biology (∼95% of all targets) to identifying a given target as probably druggable (∼95% of all targets) to structure-guided lead optimization (>70% of all small-molecule drugs). In addition to aggregate impact assessments, illustrative case studies are presented for three protein kinase inhibitors, an allosteric enzyme inhibitor and seven advanced-stage melanoma therapeutics.

SUBMITTER: Westbrook JD 

PROVIDER: S-EPMC7305983 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7325526 | biostudies-literature
| S-EPMC6190746 | biostudies-literature
| S-EPMC2792347 | biostudies-literature
| S-EPMC4068610 | biostudies-literature
| S-EPMC3965016 | biostudies-literature
| S-EPMC2808887 | biostudies-literature
| S-EPMC3013808 | biostudies-literature
| S-EPMC3245096 | biostudies-literature
| S-EPMC4601584 | biostudies-literature
| S-EPMC10478634 | biostudies-literature